Speaker illustration

Professor Edward O'Brien

Libin Cardiovascular Institute Of Alberta, Calgary (Canada)

As a seasoned clinician scientist, principal investigator and leader (e.g., former Chief of Cardiology and Director of Research for the Libin Cardiovascular Institute of Alberta), Professor Ed O'Brien has a wealth of experience in academic cardiovascular medicine. His career spans a continuum from fundamental vascular biology to interventional cardiology to his current focus on Heat Shock Protein 27 and post-menopausal vascular disease. The O'Brien laboratory has made important mechanistic insights into how HSP27 i) reduces atherogenesis by attenuating inflammation and lowering cholesterol / PCSK9 levels, and ii) improves vascular endothelial function / regeneration. The therapeutic potential for HSP27 vaccination (that capitalizes on a novel "immune-facilitated" signalling mechanism) to treat or prevent vascular and other chronic inflammatory disorders is the focus of Pemi31 Therapeutics, Inc., the company that he co-founded (see: https://pemi31therapeutics.com).

Heat Shock Protein 25 Immunotherapy Post-Menopause is Superior to Estradiol in Targeting Atherogenesis, Plasma Cholesterol and PCSK9 Levels

Event: ESC Congress 2019

Topic: Lipids, Metabolism

Session: Late Breaking Basic and Translational Science - Atherosclerosis and Aortic Stenosis


Cardiovascular risk after prophylactic salpingo-oophorectomy in patients with genetic risk of cancer

Event: EuroPrevent 2017

Topic: Risk factors and risk prediction

Session: Moderated Poster Session V - Risk factors: others


Targeting HNF1-alpha & PCSK9 in Menopause with HSP27 Replacement Rx

Event: ESC Congress 2016

Topic: Lipids

Session: Basic and Translational Science Hot Line I


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb